期刊文献+

CD15及Ki-67表达水平与乳腺癌患者病理参数及5年存活率的关系分析 被引量:9

Expression Levels of CD15 and Ki-67 and Their Relationship with Pathological Parameters and 5-year Survival Rates of Breast Cancer Patients
在线阅读 下载PDF
导出
摘要 目的探讨CD15抗原及Ki-67表达水平与乳腺癌患者病理及5年存活率的关系。方法选取2014年5月-2015年5月我院收治的乳腺癌患者手术切除的癌组织和癌旁组织(距病变部位>5 cm处,且证实为无癌浸润)石蜡标本各90例为研究对象。检测乳腺癌组织中CD15、Ki-67的表达并分析二者与乳腺癌临床病理、5年存活率的关系。结果乳腺癌组织中CD15、Ki-67的阳性表达率高于癌旁组织(P<0.05)。TNM分期Ⅱ~Ⅲ期、合并淋巴结转移的乳腺癌组织CD15、Ki-67的阳性表达率均较高(P<0.05),出现神经侵犯、直径≥2 cm的乳腺癌组织Ki-67的阳性表达率较高(P<0.05)。不同类型的乳腺癌组织Ki-67的阳性表达率比较差异有统计学意义(P<0.05)。乳腺癌组织中CD15、Ki-67表达呈正相关(r=0.406,P=0.008)。本组90例乳腺癌患者的5年总存活率为64.44%(58/90),CD15、Ki-67阳性表达组5年生存率均低于CD15、Ki-67阴性表达组(P<0.05)。结论CD15、Ki-67表达阳性与乳腺癌TNM分期、淋巴结转移有关,Ki-67的阳性表达与乳腺癌的肿瘤类型、大小、神经侵犯相关,二者与乳腺癌患者的5年存活率密切相关。 Objective To explore the relationship between expression levels of CD15 antigen and Ki-67 and pathological parameters,5-year survival rates of breast cancer patients.Methods Ninety paraffin specimens of surgical excision and 90 paraffin specimens of adjacent normal tissues(longer than 5 cm away from the lesion,confirmed as cancer-free infiltration)from the breast cancer patients who were admitted from May 2014 to May 2015 were enrolled as the research subjects.The expression levels of CD15 and Ki-67 in breast cancer tissues were detected by immunohistochemmistry.And their relationship with clinical pathological parameters and 5-year survival rates in breast cancer patients was analyzed.Results The positive expression rates of CD15 and Ki-67 in breast cancer tissues were higher than those in adjacent tissues(P<0.05).The positive expression rates of CD15 and Ki-67 were higher in TNM stageⅡ~Ⅲbreast cancer with lymph node metastasis(P<0.05),and the positive rate of Ki-67 in breast cancer with nerve invasion and diameter≥2 cm was higher(P<0.05).The positive expression rate of Ki-67 in different types of breast cancer was significantly different(P<0.05).There was a positive correlation between the expression of CD15 and Ki-67 in breast cancer(r=0.406,P=0.008).The 5-year overall survival rate of 90 breast cancer patients was 64.44%(58/90).The 5-year survival rate of CD15 and Ki-67 positive groups was lower than that of CD15 and Ki-67 negative expression groups(P<0.05).Conclusion The positive expression of CD15 and Ki-67 is related to TNM staging and lymph node metastasis of breast cancer.The positive expression of Ki-67 is related to tumor type,size and nerve invasion of breast cancer.Both are closely related to 5-year survival rates of breast cancer patients.
作者 沈玲 李海滨 罗玉群 杨辉 SHEN Ling;LI Hai-bin;LUO Yu-qun;YANG Hui(Department of Breast Surgery,Qinghai Hospital of Traditional Chinese Medicine,Xining 810000,China)
出处 《解放军医药杂志》 CAS 2020年第11期40-44,共5页 Medical & Pharmaceutical Journal of Chinese People’s Liberation Army
基金 青海省科学技术厅应用基础研究项目(2015-ZJ-504)。
关键词 乳腺肿瘤 抗原 CD15 KI-67抗原 5年存活率 肿瘤分期 肿瘤转移 危险因素 Breast neoplasms Antigens,CD15 Ki-67 antigens 5-year survival rate Neoplasm staging Neoplasm metastasis Risk factors
  • 相关文献

参考文献16

二级参考文献81

  • 1Gerdes J, Schwab U, Lemke H, et al. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation [J]. Int J Cancer, 1983, 31 ( 1 ) : 13-20.
  • 2Nishimura R, Osako T, Okumura Y, et al. Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer [J]. Exp Ther Med, 2010,1(5) :747-754.
  • 3Molino A, Micciolo R, Turazza M, et al. Ki-67 immunostaining in 322 primary breast cancers: associations with clinical and pathological variables and prognosis [J]. Int J Cancer, 1997, 74 (4) :433437.
  • 4Locker AP, Birrell K, Bell JA, et al. Ki67 immunoreactivity in breast carcinoma: relationships to prognostic variables and short term survival[J]. Eur J Surg Oncol, 1992, 18(3) :224-229.
  • 5Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours[J]. Nature, 2000, 406(6797) :747-752.
  • 6Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets [J]. Proc Natl Acad Sci USA, 2003,100(14) :8418-8423.
  • 7Railo M, Nordling S, von Boguslawsky K, et al. Prognostic value of Ki-67 iinmunolabelling in primary operable breast cancer [J] . Br J Cancer, 1993, 68 (3) :579-583.
  • 8Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer [J]. J Natl Cancer Inst, 2009, 101 (10) : 736-750.
  • 9Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes: dealing with the diversity of breast cancer: highlights of the SI. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 [J]. Ann Oncol, 2011, 22(8) :1736- 1747.
  • 10Viale G, Giobbie-Hurder A, Regan MM, et al. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole [J]. J Clin Oncol, 2008, 26 (34) :5569-5575.

共引文献228

同被引文献99

引证文献9

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部